Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy
Carmen D Zorrilla, Vivian Tamayo-AgraitDepartment of Obstetrics and Gynecology, University of Puerto Rico School of Medicine, Maternal Infant Studies Center (CEMI), San Juan, Puerto RicoAbstract: Over the past decade, significant advances have been made in the treatment of HIV-1 infection using both...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2009-12-01
|
| Series: | HIV/AIDS: Research and Palliative Care |
| Online Access: | http://www.dovepress.com/pharmacologic-and-nonpharmacologic-options-for-the-management-of-hiv-i-a3808 |
| _version_ | 1818905326902050816 |
|---|---|
| author | Carmen D Zorrilla Vivian Tamayo-Agrait |
| author_facet | Carmen D Zorrilla Vivian Tamayo-Agrait |
| author_sort | Carmen D Zorrilla |
| collection | DOAJ |
| description | Carmen D Zorrilla, Vivian Tamayo-AgraitDepartment of Obstetrics and Gynecology, University of Puerto Rico School of Medicine, Maternal Infant Studies Center (CEMI), San Juan, Puerto RicoAbstract: Over the past decade, significant advances have been made in the treatment of HIV-1 infection using both pharmacologic and nonpharmacologic strategies to prevent mother-to-child transmission (MTCT). Optimal prevention of the MTCT of HIV requires antiretroviral drugs (ARV) during pregnancy, during labor, and to the infant. ARVs reduce viral replication, lowering maternal plasma viral load and thus the likelihood of MTCT. Postexposure prophylaxis of ARV agents in newborns protect against infection following potential exposure to maternal HIV during birth. In general, the choice of an ARV for treatment of HIV-infected women during pregnancy is complicated by the need to consider the effectiveness of the therapy for the maternal disease as well as the teratogenic or teratotoxic potential of these drugs. Clinicians managing HIV in pregnancy need to discuss the potential risks and benefits of available therapy options so that mothers can make informed decisions in choosing the best treatment regimen for themselves and for their children.Keywords: HIV, pregnancy, acquired immunodeficiency syndrome, antiretroviral agents |
| first_indexed | 2024-12-19T21:21:34Z |
| format | Article |
| id | doaj.art-476c9066c288485b8edd744f252507d0 |
| institution | Directory Open Access Journal |
| issn | 1179-1373 |
| language | English |
| last_indexed | 2024-12-19T21:21:34Z |
| publishDate | 2009-12-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | HIV/AIDS: Research and Palliative Care |
| spelling | doaj.art-476c9066c288485b8edd744f252507d02022-12-21T20:05:12ZengDove Medical PressHIV/AIDS: Research and Palliative Care1179-13732009-12-012009Default4153Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancyCarmen D ZorrillaVivian Tamayo-AgraitCarmen D Zorrilla, Vivian Tamayo-AgraitDepartment of Obstetrics and Gynecology, University of Puerto Rico School of Medicine, Maternal Infant Studies Center (CEMI), San Juan, Puerto RicoAbstract: Over the past decade, significant advances have been made in the treatment of HIV-1 infection using both pharmacologic and nonpharmacologic strategies to prevent mother-to-child transmission (MTCT). Optimal prevention of the MTCT of HIV requires antiretroviral drugs (ARV) during pregnancy, during labor, and to the infant. ARVs reduce viral replication, lowering maternal plasma viral load and thus the likelihood of MTCT. Postexposure prophylaxis of ARV agents in newborns protect against infection following potential exposure to maternal HIV during birth. In general, the choice of an ARV for treatment of HIV-infected women during pregnancy is complicated by the need to consider the effectiveness of the therapy for the maternal disease as well as the teratogenic or teratotoxic potential of these drugs. Clinicians managing HIV in pregnancy need to discuss the potential risks and benefits of available therapy options so that mothers can make informed decisions in choosing the best treatment regimen for themselves and for their children.Keywords: HIV, pregnancy, acquired immunodeficiency syndrome, antiretroviral agentshttp://www.dovepress.com/pharmacologic-and-nonpharmacologic-options-for-the-management-of-hiv-i-a3808 |
| spellingShingle | Carmen D Zorrilla Vivian Tamayo-Agrait Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy HIV/AIDS: Research and Palliative Care |
| title | Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy |
| title_full | Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy |
| title_fullStr | Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy |
| title_full_unstemmed | Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy |
| title_short | Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy |
| title_sort | pharmacologic and nonpharmacologic options for the management of hiv infection during pregnancy |
| url | http://www.dovepress.com/pharmacologic-and-nonpharmacologic-options-for-the-management-of-hiv-i-a3808 |
| work_keys_str_mv | AT carmendzorrilla pharmacologicandnonpharmacologicoptionsforthemanagementofhivinfectionduringpregnancy AT viviantamayoagrait pharmacologicandnonpharmacologicoptionsforthemanagementofhivinfectionduringpregnancy |